Episode Details

Indian pharmaceutical companies have capitalized on the patent expiration of Novo Nordisks semaglutide, launching low-cost generic versions of the weight-loss and diabetes drug. This move, particularly significant in India with its large overweight population, has sparked a price war, with at least twelve major Indian firms planning their own versions. The market is set to become increasingly competitive, with companies innovating to cut costs and boost patient choice. The move is expected to significantly widen access to these life-changing drugs across India.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/1f8e5719b05d1c38